Lucia Paradiso
Overview
Explore the profile of Lucia Paradiso including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Stuart S, Bezawork-Geleta A, Areeb Z, Gomez J, Tsui V, Zulkifli A, et al.
Int J Mol Sci
. 2023 Feb;
24(4).
PMID: 36834778
Glioblastoma cells adapt to changes in glucose availability through metabolic plasticity allowing for cell survival and continued progression in low-glucose concentrations. However, the regulatory cytokine networks that govern the ability...
2.
Zulkifli A, Tan F, Areeb Z, Stuart S, Gomez J, Paradiso L, et al.
Int J Mol Sci
. 2021 Jul;
22(13).
PMID: 34281166
Cetuximab is a common treatment option for patients with wild-type K-Ras colorectal carcinoma. However, patients often display intrinsic resistance or acquire resistance to cetuximab following treatment. Here we generate two...
3.
Gomez J, Areeb Z, Stuart S, Nguyen H, Paradiso L, Zulkifli A, et al.
Cancers (Basel)
. 2021 Apr;
13(6).
PMID: 33801941
Reticulocalbin 1 (RCN1) is an endoplasmic reticulum (ER)-residing protein, involved in promoting cell survival during pathophysiological conditions that lead to ER stress. However, the key upstream receptor tyrosine kinase that...
4.
Areeb Z, Stuart S, West A, Gomez J, Nguyen H, Paradiso L, et al.
Sci Rep
. 2020 Oct;
10(1):17768.
PMID: 33082482
Despite aggressive treatment with temozolomide and radiotherapy and extensive research into alternative therapies there has been little improvement in Glioblastoma patient survival. Median survival time remains between 12 and 15 ...
5.
Morokoff A, Jones J, Nguyen H, Ma C, Lasocki A, Gaillard F, et al.
J Neurooncol
. 2020 Oct;
149(3):401.
PMID: 33026635
For the reference citation '[57]' in the second paragraph of the Results section of the original article there was no corresponding entry in the References section. It should have referred...
6.
Morokoff A, Jones J, Nguyen H, Ma C, Lasocki A, Gaillard F, et al.
J Neurooncol
. 2020 Sep;
149(3):391-400.
PMID: 32915353
Purpose: A circulating biomarker has potential to provide more accurate information for glioma progression post treatment, however no such biomarker is currently available. We aimed to discover a microRNA serum...
7.
Luwor R, Morokoff A, Amiridis S, DAbaco G, Paradiso L, Stylli S, et al.
Cancer Invest
. 2019 Mar;
37(3):144-155.
PMID: 30907150
Glioma stem cells (GSCs) play major roles in drug resistance, tumour maintenance and recurrence of glioblastoma. We investigated inhibition of the GTPase dynamin 2 as a therapy for glioblastoma. Glioma...
8.
Tan F, Putoczki T, Lou J, Hinde E, Hollande F, Giraud J, et al.
Cancers (Basel)
. 2018 Dec;
10(12).
PMID: 30572654
Signal transducer and activator of transcription 3 (STAT3) signaling is a major driver of colorectal cancer (CRC) growth, however therapeutics, which can effectively target this pathway, have so far remained...
9.
Whitehead C, Nguyen H, Morokoff A, Luwor R, Paradiso L, Kaye A, et al.
Transl Oncol
. 2018 Sep;
11(6):1406-1418.
PMID: 30219696
The most common primary central nervous system tumor in adults is the glioblastoma multiforme (GBM). The highly invasive nature of GBM cells is a significant factor resulting in the inevitable...
10.
Ma C, Nguyen H, Luwor R, Stylli S, Gogos A, Paradiso L, et al.
PLoS One
. 2018 Feb;
13(2):e0189452.
PMID: 29444091
Glioma is the most common malignant intracranial tumour. Recently, several publications have suggested that miRNAs can be used as potential diagnostic biomarkers of glioma. Here we performed a meta-analysis to...